My Account
About Us
Contact us
الواجهة العربية
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »

DuoCover is approved to prevent atherothrombotic events

DuoCover is a medicine that contains two active substances, clopidogrel and acetylsalicylic acid (also known as aspirin). It is available as oval tablets containing 75 mg clopidogrel, either with 75 mg (yellow) or 100 mg acetylsalicylic acid (pink).

DuoCover is used to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries), such as a heart attack, in adults who are already taking both clopidogrel and acetylsalicylic acid. It can be used in the following groups of patients who have a condition known as ‘acute coronary syndrome’:


  • patients who are having ‘unstable angina’ (a severe type of chest pain) or a myocardial infarction (heart attack) with no ‘ST-segment elevation’ (an abnormal reading on the ECG or electrocardiogram), including in patients having a stent (a short tube) inserted into an artery to prevent it from closing up;


  • patients being treated for heart attack with ST-segment elevation, when the doctor thinks that they would benefit from thrombolytic treatment (treatment to dissolve blood clots).

The medicine can only be obtained with a prescription.

DuoCover is taken as one tablet once a day in place of the clopidogrel and acetylsalicylic acid tablets that the patient has already been taking separately.

Both active substances in DuoCover, clopidogrel and acetylsalicylic acid, are ‘inhibitors of platelet aggregation’. This means that they help to prevent cells in the blood called platelets from aggregating (sticking together) and forming clots. Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface. This stops the platelets becoming ‘sticky’, reducing the risk of a blood clot forming. Acetylsalicylic acid stops the platelets aggregating by blocking an enzyme called prostaglandin cyclo oxygenase. This reduces the production of a substance called thromboxane, which normally helps clots to form by binding platelets together. When taken together, the two active substances can reduce the risk of problems due to blood clots forming, helping to prevent another heart attack.

Both active substances have been available in the European Union (EU) for a number of years. c has been authorised as Plavix and Iscover since 1998 for reducing platelet aggregation, and is often used in combination with acetylsalicylic acid. Acetylsalicylic acid has been available for over 100 years.

Because the two active substances have been used together for a number of years, the company presented the results of studies showing that the active substances in DuoCover are absorbed in the body in the same way as the two medicines taken separately. It also presented the results of previous studies involving over 60,000 patients with acute coronary syndrome, which showed that the combination of clopidogrel and acetylsalicylic acid taken as separate tablets was effective at preventing atherothrombotic events such as heart attacks.

DuoCover was shown to be comparable to clopidogrel and acetylsalicylic acid taken separately, and can therefore be used in place of the clopidogrel and acetylsalicylic acid tablets that the patients have already been taking.

The most common side effects with DuoCover (seen in between 1 and 10 patients in 100) are haematoma (a collection of blood under the skin), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), diarrhoea, abdominal pain (stomach ache), dyspepsia (heartburn), bruising, and bleeding where the skin is punctured. For the full list of all side effects reported with DuoCover, see the Package Leaflet.

DuoCover should not be used in people who may be hypersensitive (allergic) to clopidogrel, non steroidal anti-inflammatory drugs (such as acetylsalicylic acid) or any of the other ingredients in DuoCover. It must not be used in patients who have a disease that is causing bleeding, such as stomach ulcer or bleeding in the brain. It must not be used in patients who have severe liver or kidney problems, or who have a medical condition that includes a combination of asthma, rhinitis (stuffy and runny nose) and nasal polyps (growths in the lining of the nose). DuoCover must not be used during the last three months of pregnancy.

The Committee for Medicinal Products for Human Use (CHMP) noted that DuoCover is comparable to clopidogrel and acetylsalicylic acid tablets taken separately, and concluded that combining both active substances in a single DuoCover tablet simplifies treatment for patients as they will need to take fewer tablets. The Committee therefore decided that DuoCover’s benefits are greater than its risks and recommended that it be given marketing authorisation.

The European Commission granted a marketing authorisation valid throughout the EU for DuoCover to Bristol Myers Squibb Pharma EEIG on 15 March 2010. The marketing authorisation is valid for five years, after which it can be renewed.

اضغط هنا للقراءة باللغة العربية

Source :

European Medicine Agency

Other Comments

Add a comment

You must sign in to use this servcie


facebook comments

Forgot your password

sign up

Consultants Corner

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist

Dr. Talal Sabouni


Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details